If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 6 of 6
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology or Other Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Objective
A Dose-Escalation Study of XL092 in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Protocol No
EXELIXIS-XL092-002
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Sol
Objective
A Phase 1A 1B Study of TEV-56278 in Patients with Selected Locally Advanced or Metastatic Solid Tumors
Protocol No
TEVA-TV56278-ONC-10203
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
Objective
Comparing Sentinel Lymph Node (SLN) Biopsy with Standard Neck Dissection for patients with early-stage oral cavity cancer.
Protocol No
NRG-HN006
Categories
A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Objective
Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary HNSCC
Protocol No
ECOG-EA3191
Categories
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)
Objective
A Phase II study of Re-Irradiation Utilizing DIR and OAR Dose Calculations with Organ Specific Toxicity Analysis
Protocol No
IIT-GORE-REDIRICT
Categories
Cancer,
Lip, Oral Cavity and Pharynx,
Cervix,
Melanoma, Skin,
Skin Cancers,
Prostate and Urologic Cancers,
Breast Cancers,
Other Gastrointestinal,
Gynecologic Cancers,
Thoracic Cancers,
Pancreas/Liver,
Esophagus,
Colorectal,
Endocrine Cancers,
Gastrointestinal Cancers,
Sarcoma,
Larynx,
Brain and Spine Cancers,
Head and Neck Cancers
Immunotherapy and Nodal-Sparing Irradiation for T Cell Induction and Unmasking of Tumor Antigenicity in the Microenvironment for Head and Neck Cancer
Objective
Immunotherapy and Nodal-sparing Irradiation for T Cell Induction and Unmasking of Tumor Antigenicity
Protocol No
IIT-AWAN-INITIUM-HN
Categories